Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity

References

• Yáñez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015;4:27066.
   PubMed Web of Science ®Google Scholar
• Fais S, O’Driscoll L, Borras FE, et al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano 2016;10:3886–99.
   PubMed Web of Science ®Google Scholar
• Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009;284:34211–22.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442–52.
   PubMed Web of Science ®Google Scholar
• Gallala HD, Sandhoff K. Biological function of the cellular lipid BMP-BMP as a key activator for cholesterol sorting and membrane digestion. Neurochem Res 2011;36:1594–600.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Angelini DF, Iessi E, et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett 2017;403:318–29.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891–9.
   PubMed Web of Science ®Google Scholar
• Lugini L, Matarrese P, Tinari A, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006;66:3629–38.
   PubMed Web of Science ®Google Scholar
• De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007;67:5408–17.
   PubMed Web of Science ®Google Scholar
• Spugnini E, Fais S. Proton pump inhibition and cancer therapeutics: a specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin Cancer Biol 2017;43:111–8.
   PubMed Web of Science ®Google Scholar
• De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010;127:207–19.
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004;96:1702–13.
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012;72:2746–56.
   PubMed Web of Science ®Google Scholar
• Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 2014;33:1095–108.
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015;356:697–703.
   PubMed Web of Science ®Google Scholar
• Azzarito T, Lugini L, Spugnini EP, et al. Effect of modified alkaline supplementation on syngenic melanoma growth in CB57/BL mice. PLoS ONE 2016;11:e0159763.
   PubMed Web of Science ®Google Scholar
• Canitano A, Iessi E, Spugnini EP, et al. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett 2016;376:278–83.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430–50.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85–95.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 2017;8:2.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956;123:309–14.
   PubMed Web of Science ®Google Scholar
• Semenza GL, Artemov D, Bedi A, et al. The metabolism of tumours: 70 years later. Novartis Found Symp 2001;240:251–60.
   PubMedGoogle Scholar
• Xu XD, Shao SX, Jiang HP, et al. Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncol Res Treat 2015;38:117–22.
   PubMed Web of Science ®Google Scholar
• Icard P, Shulman S, Farhat D, et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat 2018;38:1–11.
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441–54.
   PubMed Web of Science ®Google Scholar
• Newell K, Franchi A, Pouysségur J, Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 1993;90:1127–31.
   PubMed Web of Science ®Google Scholar
• Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998;77:1726–31.
   PubMed Web of Science ®Google Scholar
• Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002;8:1284–91.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439–45.
   PubMed Web of Science ®Google Scholar
• Mookerjee SA, Goncalves RLS, Gerencser AA, et al. The contributions of respiration and glycolysis to extracellular acid production. Biochim Biophys Acta 2015;1847:171–81.
   PubMed Web of Science ®Google Scholar
• Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 2017;17:577–93.
   PubMed Web of Science ®Google Scholar
• Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541–9.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Sonveaux P, Stock C, et al. Proton channels and exchangers in cancer. Biochim Biophys Acta 2015;1848:2715–26.
   PubMed Web of Science ®Google Scholar
• Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis 2010;1:e87.
   PubMed Web of Science ®Google Scholar
• Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007;67:10627–30.
   PubMed Web of Science ®Google Scholar
• Lugini L, Federici C, Borghi M, et al. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem 2016;31:538–45.
   PubMed Web of Science ®Google Scholar
• Lu Z-N, Tian B, Guo X-L. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925–37.
   PubMed Web of Science ®Google Scholar
• Gorbatenko A, Olesen CW, Boedtkjer E, Pedersen SF. Regulation and roles of bicarbonate transporters in cancer. Front Physiol 2014;5:130.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76.
   PubMed Web of Science ®Google Scholar
• a) Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902;
   PubMed Web of Science ®Google Scholar
  b) Krall N, Pretto F, Decurtins W, et al. A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5;
   PubMed Web of Science ®Google Scholar
  c) Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem 2018;61:6328–38;
   Google Scholar
  d) Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 1999;7:2397–406.
   PubMed Web of Science ®Google Scholar
• a) McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites 2018;8:E2;
   Web of Science ®Google Scholar
  b) Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. OncoImmunology 2018;7:e1445452.
   PubMed Web of Science ®Google Scholar
• Kaluz S, Kaluzová M, Liao S-Y, et al. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2009;1795:162–72.
   PubMed Web of Science ®Google Scholar
• a) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–77;
   PubMed Web of Science ®Google Scholar
  b) Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat 2013;23:737–49.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48;
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:E25.
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017;2:92928. Available at: https://insight.jci.org/articles/view/92928
   PubMed Web of Science ®Google Scholar
• Pastoreková S, Závadová Z, Kostál M, et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620–6.
   PubMed Web of Science ®Google Scholar
• a) Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569–79;
   PubMed Web of Science ®Google Scholar
  b) Kusuzaki K, Matsubara T, Murata H, et al. Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery? J Enzyme Inhib Med Chem 2017;32:908–16.
   PubMed Web of Science ®Google Scholar
• Chen LQ, Howison CM, Spier C, et al. Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk Lymphoma 2015;56:1432–9.
   PubMed Web of Science ®Google Scholar
• a) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68;
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• a) Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med 2017;95:1341–53;
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60;
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Horie K, Kawakami K, Fujita Y, et al. Exosomes expressing carbonic anhydrase 9 promote angiogenesis. Biochem Biophys Res Commun 2017;492:356–61.
   PubMed Web of Science ®Google Scholar
• Reshkin SJ, Greco MR, Cardone RA. Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond, B, Biol Sci 2014;369:20130100.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int 2008;101:8–15.
   PubMed Web of Science ®Google Scholar
• Cianchi F, Vinci MC, Supuran CT, et al. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010;334:710–9.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem 2016;31:119–25.
   PubMed Web of Science ®Google Scholar
• a) Mahmood S-U, Saeed A, Bua S, et al. Synthesis, biological evaluation and computational studies of novel iminothiazolidinone benzenesulfonamides as potent carbonic anhydrase II and IX inhibitors. Bioorg Chem 2018;77:381–6;
   PubMed Web of Science ®Google Scholar
  b) Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721–7;
   PubMed Web of Science ®Google Scholar
  c) Supuran CT, Mincione F, Scozzafava A, et al. Carbonic anhydrase inhibitors—part 52. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents in rabbits. Eur J Med Chem 1998;33:247–54;
   Web of Science ®Google Scholar
  d) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–8;
   PubMed Web of Science ®Google Scholar
  e) Şentürk M, Gülçin İ, Beydemir Ş, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494–9.
   PubMed Web of Science ®Google Scholar
• a) Métayer B, Angeli A, Mingot A, et al. Fluoroenesulphonamides: N-sulphonylurea isosteres showing nanomolar selective cancer-related transmembrane human carbonic anhydrase inhibition. J Enzyme Inhib Med Chem 2018;33:804–8;
   PubMed Web of Science ®Google Scholar
  b) Rehman SU, Chohan ZH, Gulnaz F, Supuran CT. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J Enzyme Inhib Med Chem 2005;20:333–40;
   PubMed Web of Science ®Google Scholar
  c) Clare BW, Supuran CT. Carbonic anhydrase activators. 3: Structure‐activity correlations for a series of isozyme II activators. J Pharm Sci 1994;83:768–73;
   PubMed Web of Science ®Google Scholar
  d) Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424–31;
   PubMed Web of Science ®Google Scholar
  e) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94;
   PubMed Web of Science ®Google Scholar
  f) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11.
   PubMed Web of Science ®Google Scholar
• Khalyfa A, Almendros I, Gileles-Hillel A, et al. Circulating exosomes potentiate tumor malignant properties in a mouse model of chronic sleep fragmentation. Oncotarget 2016;7:54676–90.
   PubMedGoogle Scholar
• Zhao H, Achreja A, Iessi E, et al. The key role of extracellular vesicles in the metastatic process. Biochim Biophys Acta 2018;1869:64–77.
   PubMed Web of Science ®Google Scholar
• Federici C, Petrucci F, Caimi S, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 2014;9:e88193.
   PubMed Web of Science ®Google Scholar
• Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 2009;4:e5219.
   PubMed Web of Science ®Google Scholar
• Cappello F, Logozzi M, Campanella C, et al. Reprint of exosome levels in human body fluids: a tumor marker by themselves? Eur J Pharm Sci 2017;98:64–9.
   PubMed Web of Science ®Google Scholar
• Ambrosio MR, Di Serio C, Danza G, et al. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol 2016;11:45.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Oosterwijk E, et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 2009;386:488–92.
   PubMed Web of Science ®Google Scholar
• Juhász M, Chen J, Lendeckel U, et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther 2003;18:837–46.
   PubMed Web of Science ®Google Scholar
• Csaderova L, Debreova M, Radvak P, et al. The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Frontier Physiol 2013;4:271.
   PubMed Web of Science ®Google Scholar
• Ramteke A, Ting H, Agarwal C, et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog 2015;54:554–65.
   PubMed Web of Science ®Google Scholar